initi coverag
initi neutral alreadi give credit key near-term pipelin asset
invest summari initi coverag neutral
price target commerci stage hematology/oncolog compani
lead asset jakafi market treat patient myelofibrosi
polycythemia vera think variou readout next month
also think appropri valu compani key mileston
look pipelin opportun current valu drive greater
upsid valuat think opportun horizon
remain littl earli opinion
remain posit jakafi franchis believ continu
grow mani year peak estim close cautiou yet
assign higher sale estim see commerci trend evolv clinic
success indic expans model jakafi sale vs
think product mani year doubl digit growth left
think factor factset consensu
includ valu late stage pipelin like fgfr gvhd reflect
reason credit valuat alreadi think program
like succeed investor agre make risk/reward unattract
setback risk thesi would itacitinib robust durat
could make big product assum probabl success
sale
believ key unlock market cap valu stori
show product think next month
critic period prove investor reason level investor
discuss around compani spend current spend level
expect growth next two year believ
abl replenish pipelin support level spend take
time earlier stage catalyst play program watch
itacitinib novel immuno-oncolog combin
disclosur section may found page
initi coverag
surpris break-out pipelin item key upsid alreadi give signific credit late stage
incyt corpor wilmington delaware-bas biopharmaceut compani focus
discoveri develop commerci proprietari therapeut first
commerci product jakafi ruxolitinib approv unit state patient
intermedi high-risk myelofibrosi patient polycythemia vera
inadequ respons intoler hydroxyurea
remain posit jakafi franchis myelofibrosi
polycythemia vera think variou readout next
month also think appropri valu compani
key mileston
event watch
investor debat
think spend go forward post
compani focus innov wouldnt expect
dramat cut spend sinc life blood compani think
compani may give color line item futur
pipelin product focu next month
think itacitinib interest program watch
durat also think jaki combin work interest
scientif rational like itacitinib ruxolitinib
think compani acquir
think risk neutral thesi compani acquir
seem like would happen pipelin readout
exhibit catalyst drug franchis next month catalystdrugtargetdata open-label patient present topic ruxolitinib atop dermatitistop ruxolitinibjak vitiligo random doubl blind topic ruxolitinibjak open-label advanc ruxolitinibpimi open label patient afer take steriod refractori acut gvhd full acut vs best care chronic newli diagnos acut patient patient metastat bladder indol lymphoma aggress data high endometri cancer cantor fitzgerald research neutral pt
valuat rate share neutral price target valuat deriv dcf-base analysi
probabl adjust pipelin revenu stream assum discount rate termin growth assumpt
short interest float
day cover short
upsid current market price
factset
total
compani report factset research cantor fitzgerald research
commerci stage hematolog oncolog compani
jakafi compani lead program treat myelofibrosi polycythemia vera
jakafi domin treatment space though celgen celg ow fedratinib
approv could provid competit
setback ido inhibitor program refocus pipelin variou key
incyt thesi valuat call look pipelin surpris
alreadi give compani credit mani key program
launch neutral rate pt
think jakafi franchis myelofibrosi pv continu grow though dont see
signific upsid project
posit late stage pipelin like fgfr gvhd reflect reason credit
valuat alreadi think program like succeed investor agre
make risk/reward unattract
believ key unlock market cap valu stori show
product think next month critic period prove
look pipelin surpris would drive upsid valuat
chang sinc prior coverag neutral mostli valuat call
still think compani emerg pipelin oncolog asset
share weak due setback epacadostat melanoma
jakafi estim current two indic rel unchang
review commerci estim clinic data pipelin opportun
pipelin revenu differ except remov epacadostat ad
new program explicitli model like
met incyt ceo head clinic head recent
reflect past present futur onward upward commerci stori
leverag jak biolog expertis pipelin
think investor want see pipelin success quit horizon
comfort compani execut jakafi
think compani show success pipelin readout stock work
exhibit cantor reflect stand stori
come past
month stori
inhibitor epacadostat would work pivot melanoma studi
bear correct studi work
discontinu clinic develop epacadostat meaning way
mani earlier clinic program continu background
like gvhd fgfr overshadow epacadostat
current stori
investor event review pipelin key timelin
late stage readout next month also
discuss rational start earlier stage combin
investor debat right level spend
compani compris current spend
go stori
expect get mani pivot readout especi
expect jakafi two current indic continu
grow acut steriod refractori gvhd may third indic
end
compani continu start new studi base convict
discoveri engin
incyt main revenu engin jakafi mani pipelin asset focus jak biolog
scienc driven compani focus hematolog oncolog indic
lead asset jakafi current market mylelofibrosi mf polycythemia vera
book revenu jakafi us novarti nv cover pay
royalti ex-u jakavi
get royalti louis chen jak call olumi recent
discoveri engin clinic program mani program
earli
broad pipelin fair amount emerg opportun valu mani opportun
achiev proof concept
much pipelin come intern discoveri effort
product market intern discoveri
made progress mani program post april
pipelin event medic meet april
includ think support view compani clearli
pipelin epacadostat though admit biggest commerci
view mani pipelin program mani success
meaning revenu line
think pipelin also well-balanc new product data possibl come
market next year
continu discoveri develop key
exhibit show new product data next three year
think pipelin make one attract compani new product
diversifi current oper
exhibit incyt product launch year
earli stage data beyond
b-cell pathogen
mani late-stag data readout next month
within coverag univers catalyst list probabl one longest new assets/ind
also view mani readout high import stock price
exhibit incyt catalyst drug franchis next month
combo
ph present topic ruxolitinib atop
open-label patient myelofibrosi
pimi combo
open label patient afer take ruxolitinib
combo
acut vs best care chronic
fight patient cholangiocarcinoma
fight patient metastat bladder
citadel indol lymphoma aggress
registr data high endometri
registr data merkel cell carcinoma
registr data anal cell cancer
incyt compani present cantor fitzgerald research
base case assum pipelin peak sale franchis
unadjust pipelin peak revenu
itacitinib steroid nave gvhd biggest opportun pipelin perspect
exhibit base case pipelin revenu cantor fitzgerald fgfr itacitinib nave gvhd ruxolitinib expans refractori franchis emerg larg cap univers growth in-lin peer
ep grow fast sinc compani earli stage profit
consensu project top bottom-lin compound-annual-growth-rate
exhibit rel revenu compound-annual-growth-rate emerg larg cap stockssourc factset cantor rel ep compound-annual-growth-rate emerg larg cap stockssourc factset cantor valuat use probabl adjust dcf analysi
month target price
dcf valuat
chang work capit
present valu flow
npv
npv termin valu
tv total
focus due dilig get right next month
major report focus due dilig topic
jakafi commerci launch us
still see greater penetr pv indic
ask incyt driver launch beat expect
see full data gvhd
mani catalyst horizon discuss detail
oper expens spend return spend
believ spend essenti part pipelin stori
done work tri figur reason level spend
investor debat view
debat high level view
appropri level spend think annual
spend
good part associ discoveri big part compani
compani consid give street detail understand
think pipelin post epacadostat data
compani pipelin asset broad smaller epacadostat
think ad smaller opportun meaning
think target point
think jakafi franchis probabl bigger opportun current reflect
cautiou make invest thesi
deal happen would think reason time-frame
risk weaker commerci sale clinic safeti issu pipelin asset
think share volatil jakafi revenu pipelin setback
weaker expect revenu jakafi current market two indic
jakafi still import commerci asset compani remain
confid growth trajectori
would expect volatil jakafi could keep pace consensu revenu
pipelin failur due lack efficaci safeti concern
late stage clinic setback includ ruxolitinib gvhd itacitinib gvhd two
program either complet proceed toward complet
sinc discoveri compani clinic setback lead lack investor
confid compani abil discov new asset
oper expenditur lead product use capit
risk doesnt effect select pipelin product ultim lead
jakafi ruxolitinib remain pipelin
in-lin long-term guidanc jakafi slightli consensu
current long-term guidanc us jakafi revenu
believ like upsid long-term expect jakafi
grow think patient experi increas awar abil
diagnosi diseas increas especi pv
exhibit jakafi us revenu cantor vs consensu sourc cantor fitzgerald us- cantor usjakafi us- consensu septemb
view gvhd increment opportun rel mf pv
current long-term guidanc us jakafi revenu
within guidanc includ sale mf pv gvhd
would estim roughli coupl hundr million bake steroid refractori
could upsid come current indic greater penetr
loss
small
exhibit jakafi us revenu indicationsourc cantor fitzgerald mfjakafi pvjakafi gvhd septemb
dont model expans opportun ruxolitnib though get proof
concept data
current guidanc bake expans
interest rux itacitinib combin studi sinc increment
benefit spleen symptom reduct cytopenia issu
pim inhibit could link inhibit pathway pim kinas
pathway report somehow connect
combin look viabl could lead longer ip would expect compani
exhibit expand leadership ruxolitinib
ruxolitinib combin
ruxolitinib combin pim
initi data
ruxolitinib itacitinib
initi data
model coformul
would life cycl strategi
dont model co-formul
would life cycl strategi
interest could open
refractori market rux
model regulatori
discuss underway
model opportun
hope start
upsid pipelin
view itacitinib promis pipelin asset incyt
pivot program gravita underway steroid nave patient data expect
previou work present american societi hematolog meet
compani also announc expand gravita program studi
chronic gvhd prophylaxi
model sale chronic prophyalxi
prior data small number patient support proof concept itacitinib
patient studi present american societi hematolog meet
overal respons rate orr steroid nave patient dose
complet respons cr rate studi fairli small patient first-lin
steroid refractori
data report day respons achiev
median durat day mo
efficaci robust steroid refractori
peak sale risk-adjust itacitinib
get full econom program manag intend commerci
key metric watch data readout durat treatment
assum month steroid nave would upsid estim
durat turn longer year
assum peak market share steroid nave gvhd patient
ip
us ex-u
exhibit cantor itacitinib sale geographysourc cantor fitzgerald usitacitinib ex-u also interest itacitinib/ruxolitinib combo rux refractori patient
would new market rux franchis
could add
shown activ spleen reduct symptomat improv
use robust definit rux refractori patient
success open door new market co-formul strategi
competitor like celgen suggest rux refractori market could repres
opportun base estim
current dont model opportun
although cautiou commerci situat think chosen opportun
could distinct
expect pivot data indic immuno-oncolog
high endometri cancer awar merck nc label tesaro
tsro ow also studi pivot studi
estim us incid patient msi-h endometri cancer
less awar compani develop merkel anal cancer
overal look similar develop
acquir cover
initi data present dose escal studi meet late call
overal efficaci safeti look compar pembrolizumab overal
confid antibodi make
clearli crowd space build viabl commerci strategi key
inci fgfr inhibitor pivot develop two oncolog type
compani on-going potenti registr studi fgfr-mutat cholangiocarcinoma patient
bladder cancer patient
transloc fusion estim icca patient
cholangiocarcinoma interim phase ii data look promis compani complet
recruit patient evalu final respons rate overal durat respons
support potenti file
regulatori bar approv look favor current standard care chemotherapi
orr median month line icca patient
think competit limit fgfr icca current arql basilea bsln ow
cover louis chen derazantinib novarti nv uncov bridgebio infigratinib two
notabl fgfr inhibitor icca indic
bladder cancer inci agent current behind competitor jnj erdafitinib timelin
current well-posit fgfr cholangiocarcinoma space
inci phase ii open-label single-arm studi evalu advanc
cholangiocarcinoma patient primarili patient transloc fail
compani plan file nda potenti acceler approv
compani also plan initi random phase studi vs gemcitabin plu cisplatin
chemo first-lin cholangiocarcinoma patient trial initi expect
exhibit studi design fgfr cholangiocarcinoma
interim respons data promis need hold larger cohort
report unconfirm orr evalu patient patient
pr confirm pr unconfirm on-going await confirm
median month
exhibit efficaci fgfr-transloc patient
competit landscap limit fgfr-mutat icca indic
arql basilea derazantinib on-going registr studi line fusion
interim data expect
derazantinib achiev orr phase i/ii studi
novarti nv uncov bridgebio infigratinib current phase ii clinic studi patient
infigratinib achiev orr fusion cholangiocarcinoma patient
on-going studi bladder cancer
on-going phase ii studi mutat bladder cancer patient progress
earlier line therapi
compani adjust studi includ addit arm continu dose regimen
 share promis result year
continu treatment arm expect data
compani plan file regulatori approv base phase ii result
exhibit studi design fgfr-mutat bladder cancer
inci agent current behind competitor jnj erdafitinib timelin clinic activ
interim result patient use intermitt dose regimen
report unconfirm orr evalu patient patient
pr confirm pr unconfirm on-going await confirm
exhibit efficaci fgfr-mutat bladder cancer patient
inci agent current behind competitor jnj erdafitinib timelin clinic activ
competitor jnj erdafitinib report orr fgfr-alter bladder cancer patient phase
ii studi year
median durat respons month median month median os
pdufa erdafitinib expect around septemb fgfr-alter bladder cancer
later line
exhibit erdafitinib fgfr-mutat bladder cancer patient
well valid target nhl space need show differenti profil
pursu inhibitor three differ form non-hodgkin lymphoma nhl
follicular lymphoma fl margin zone mzl mantl cell lymphoma mcl
fl highest global incid follow mzl mcl around
rituxan wide use standard care fl therapi symptomat high-tumor burden fl includ
addit rituxan convent chemotherapi
three inhibitor current approv line fl set exhibit
inhibitor earlier report similar respons rate pivot studi fl
ow zydelig bayer aliqopa vstm copiktra
exhibit approv target agent follicular lymphoma
r/r rituxan w/ bendamustin
earlier phase i/ii result show clear activ trial size howev small assess
show clear activ phase i/ii citadel studi
exhibit phase i/ii respons rate r/r nhl
believ drug select delta isoform vs agent
citadel studi expect initi data
on-going phase ii studi assess safeti efficaci subject
relaps refractori non-hodgkin lymphoma nhl
studi on-going follicular lymphoma fl margin zone mzl mantl cell lymphoma mcl
three monotherapi trial potenti registr could lead acceler approv
indic
initi data expect
variou combin regimen on-going inhibitor
inci inhibitor molecul design significantli minim hepatotox risk accord
manag
manag believ drug competit safeti profil two key class-rel safeti
issu liver toxic cumul immun coliti well manag drug
toler profil key combin studi class gener usual
associ poor safeti profil
exhibit combin studi on-going inhibitor
join presid chief execut offic appoint
chairman board director
prior presid novarti oncolog
join execut vice presid chief offic octob
prior chief offic celgen corpor scio inc
join member found scientif team januari
prior dupont bristol-my squibb compani
join senior vice presid chief medic offic march
prior novarti pharmaceut corpor
incom statement except ep
product revenu base busi
product revenu pipelin prob adjust
incom tax non-gaap
provis benefit incom tax non-gaap
basic share use comput ep
dilut share use comput ep
total cost expens
incom loss oper
incom loss provis incom tax
balanc sheet
cash equival short-term
prepaid expens current
properti plant equip net
intang asset net
current portion long-term debt
total liabil equiti
flow statement
adjust non-oper item
depreci amort
chang
prepaid expens asset
accru expens liabil
purchas available-for-sal secur
proce matur sale market secur
chang
end ce short-term market secur
incyt corpor wilmington delaware-bas biopharmaceut compani focus discoveri develop
commerci proprietari therapeut first commerci product jakafi ruxolitinib approv unit state
patient intermedi high-risk myelofibrosi patient polycythemia vera inadequ respons
intoler hydroxyurea
